India Pharma Outlook Team | Monday, 31 August 2026
Aurobindo Pharma has marked a major milestone as its US subsidiary Lannett Company LLC launched the generic version of Advair Diskus in the American market on 31 August 2026.
The product reaches patients in two strengths, 100/50 mcg and 250/50 mcg. This launch represents the first commercial inhalation product from Aurobindo’s pipeline and expands access to a widely prescribed combination therapy for asthma and chronic obstructive pulmonary disease.
Lannett, a wholly owned subsidiary of Aurobindo Pharma USA, developed and commercialized the fluticasone propionate and salmeterol inhalation powder.
The move strengthens the company’s presence in complex respiratory generics and signals progress in its high-barrier product strategy.
Lannett Company LLC has commercialized the generic equivalent of Advair Diskus (fluticasone propionate and salmeterol inhalation powder). The company offers the inhaler in two strengths: 100/50 mcg and 250/50 mcg.
Advair Diskus is a combination therapy that doctors prescribe for the treatment of asthma and chronic obstructive pulmonary disease. The original product comes from GSK. The generic version expands patient options in the US respiratory market. This launch marks Lannett’s first product from its inhalation pipeline to reach the commercial stage in the United States.
Also Read: Why Peptides and Complex Generics Will Define India Pharma's Future
Aurobindo Pharma has focused on building capabilities in complex and differentiated products beyond conventional oral solid formulations. The successful commercialization of this inhalation therapy demonstrates progress in that direction.
The company continues to develop its broader inhalation pipeline. Officials describe the launch as part of a continued effort to expand the portfolio of complex respiratory drug delivery products in the US market. The addition strengthens Aurobindo’s overall US generics portfolio and positions the group more firmly in the high-barrier inhalation segment.
The generic Advair Diskus provides a lower-cost alternative for patients who rely on this combination inhaler for asthma and COPD management. Availability in two commonly used strengths allows doctors and patients to match the appropriate dose.
Lannett has brought the product to market as the first commercial offering from its inhalation pipeline. The company highlights the launch as a reflection of its focus on expanding complex and differentiated inhalation products. Aurobindo Pharma’s subsidiary has now established a commercial presence in the inhalation therapeutics space with this debut product.
The launch underscores Aurobindo’s strategic push into complex generics. Inhalation products involve higher technical barriers than traditional oral solids, and successful commercialization validates the company’s development capabilities in this area.
Aurobindo continues work on additional inhalation candidates. The company aims to build a broader portfolio of differentiated respiratory products for the US market. With the generic Advair Diskus now available, Lannett and Aurobindo have converted pipeline progress into a tangible commercial offering for American patients.
.jpg)
